Last mentioned: Mar 22, 2026
Market Outperformance
Grail shares end the week as a top performer in the healthcare sector, recouping major losses.
Market Outperformance
Financial media highlights Grail as the week's top performer in the diagnostics sector.
Market Outperformance
Grail shares surge as market sentiment shifts from bearish to bullish, leading the biotech sector gains.
Volume Surge
Stock sees highest trading volume in six months as institutional buyers return.
TD Cowen Upgrade
TD Cowen upgrades Grail to 'Buy,' arguing the market overreacted to the leadership change.
TD Cowen Upgrade
Analysts upgrade Grail to 'Buy,' citing an oversold condition and strong core fundamentals.
TD Cowen Upgrade
Analysts upgrade GRAL, calling the recent selloff a 'buying opportunity' and stabilizing the stock price.
Market Low
GRAL stock hits a 52-week low amid heavy selling pressure.
CEO Transition & Setback
CEO Bob Ragusa retires following reports of a clinical trial setback, causing a sharp drop in GRAL shares.
CEO Transition
Bob Ragusa steps down as CEO following reports of a trial setback.
Leadership & Trial Volatility
CEO Bob Ragusa announces retirement; reports surface regarding a setback in the NHS-Galleri clinical trial.
Candel Public Offering
Candel Therapeutics prices $100M public offering at $5.45 per share.
Trial Data Release
Grail shares slide as NHS-Galleri trial misses primary endpoint for late-stage cancer reduction.
GDP Release
U.S. government scheduled to release Q4 GDP growth figures at 8:30 AM ET.
Grail Earnings
Grail reports Q4 and Full Year 2025 financial results, beating revenue and EPS estimates.
After a volatile start to March marked by a CEO transition and clinical trial setbacks, Grail (GRAL) shares staged a massive recovery this week. The rebound was fueled by a high-profile analyst upgrade and a market correction following what many saw as an overreaction to recent headwinds.
Grail (GRAL) shares outperformed the broader market this week, staging a dramatic recovery following a sharp selloff earlier in the month. Investor sentiment shifted after a key analyst upgrade and a reassessment of the long-term impact of a recent clinical trial setback.
Grail (GRAL) shares staged a significant recovery this week, outperforming the broader market following a period of heavy selling. The rebound was driven by a high-profile analyst upgrade and a shift in investor sentiment regarding the company's multi-cancer early detection (MCED) platform.
Grail (GRAL) stock staged a major recovery this week, outperforming the broader market after a pivotal upgrade from TD Cowen. The rally marks a significant shift in investor sentiment following a volatile period triggered by a CEO transition and clinical trial concerns.
US equity futures signaled a positive open on Friday as investors shifted focus toward the release of fourth-quarter GDP figures. Following a lackluster Thursday session, the market is looking for confirmation of economic resilience while monitoring individual movers like Grail and Candel Therapeutics.